Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2003
08/20/2003CN1437462A Effervescence particles and preparing method thereof
08/20/2003CN1437461A Cosmetic or dermatological cream composition, the preparation and the use thereof
08/20/2003CN1436804A Oligomeric or polymerized methylene protein and its separation and purification process and use
08/20/2003CN1118531C Commonly used buffer salt tablet and its preparation
08/20/2003CN1118240C Application of liquid saccharides fermentation product in foods
08/19/2003US6608108 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
08/19/2003US6608076 Treating topoisomerase I inhibitor-related disease in mammals
08/19/2003US6608043 Administering complex of hyaluronic acid and zinc to patient having arthritic disease
08/19/2003US6608034 Immunovectors for the intracellular and intranuclear transport
08/19/2003US6607778 Solid delivery systems for aroma ingredients
08/19/2003US6607752 Forming a nicotine/cation exchange resin solvent mixture by blending nicotine, resin and solvent together, maintaining the solvnet in liquid state for a second by controlling pressure and temperature, then evaporation the solvent
08/19/2003US6607750 Directly compressible acetaminophen compositions
08/19/2003US6607749 Non-fermentable methyl cellulose, lipase inhibitor and edible calcium phosphate salt; fecal incontinence, obesity
08/19/2003US6607748 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
08/19/2003US6607742 Suppository composition which is a spray-dried suspension of an acid-labile proton pump inhibitor in a solvent solution of a sterol and polymer
08/19/2003US6607732 ISCOM or ISCOM-matrix comprising a mucous targetting substance and an antigen
08/19/2003CA2138149C Stables compositions of microgranules of gastro-protected omeprazole and process for their preparation
08/19/2003CA2108026C Inhibition of aggregation of drug containing particles
08/19/2003CA2091165C Polymers containing diester units
08/19/2003CA2033122C Anti-inflammatory analgesic patch
08/15/2003CA2373918A1 Polo domain structure
08/14/2003WO2003067209A2 Ligands to enhance cellular uptake of biomolecules
08/14/2003WO2003066859A2 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003WO2003066824A2 Albumin-fused kunitz domain peptides
08/14/2003WO2003066681A1 Stabilization of protein preparations
08/14/2003WO2003066656A1 Crystalline complexes of fluticasone 2-furoate
08/14/2003WO2003066655A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
08/14/2003WO2003066585A2 Polymer-based compositions for sustained release
08/14/2003WO2003066209A1 Encapsulation process and encapsulated compositions
08/14/2003WO2003066205A2 Microcapsules having high carotenoid content
08/14/2003WO2003066130A2 Transdermal drug delivery systems
08/14/2003WO2003066104A2 Pharmaceutical composition which improves in vivo gene transfer
08/14/2003WO2003066103A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
08/14/2003WO2003066102A1 Immunocytokine-containing lyophilized preparation
08/14/2003WO2003066101A1 Preparation for oxidation-sensitive compounds and method for making same
08/14/2003WO2003066096A1 Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
08/14/2003WO2003066090A1 Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
08/14/2003WO2003066085A1 Albumin-fused anti-angiogenesis peptides
08/14/2003WO2003066078A1 Hiv inhibiting proteins
08/14/2003WO2003066073A2 Compositions containing oat straw and willowherb extract
08/14/2003WO2003066069A1 Polymers for delivering peptides and small molecules in vivo
08/14/2003WO2003066068A1 Hpma-polyamine conjugates and uses therefore
08/14/2003WO2003066067A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
08/14/2003WO2003066065A1 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
08/14/2003WO2003066064A2 Methods of resistant bacterial disease treatment using metal-complexed tetracycline antibiotics
08/14/2003WO2003066063A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
08/14/2003WO2003066038A1 Process to prepare semicarbazones’ and/or tiosemicarbazones’ formulations using cyclodextrins and their derivatives and products obtained by this process
08/14/2003WO2003066036A1 Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions
08/14/2003WO2003066033A1 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
08/14/2003WO2003066032A1 Formulations for inhalation
08/14/2003WO2003066031A1 Cyclodextrines for use as suspension stabilizers in pressure-liquefied propellants
08/14/2003WO2003066030A2 Pharmaceutical tablet
08/14/2003WO2003066029A2 Pharmaceutical dosage form for mucosal delivery
08/14/2003WO2003066028A1 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
08/14/2003WO2003066026A1 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier
08/14/2003WO2003066025A1 Clear micellized formulations of beta-carotene for treating leukoplakia
08/14/2003WO2003066024A1 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
08/14/2003WO2003066023A1 A stable pharmaceutical formulation comprising torsemide modification ii
08/14/2003WO2003066022A2 Stable pharmaceutical composition useful for treating gastrointestinal disorders
08/14/2003WO2003066021A2 Drug nanoparticles with lysozyme surface stabiliser
08/14/2003WO2003066020A1 Composition for easing human childbirth
08/14/2003WO2003066012A1 Preparations containing diol
08/14/2003WO2003066009A1 Topical ivermectin composition
08/14/2003WO2003066004A2 Therapeutic compounds
08/14/2003WO2003066003A2 Anti-pathogen treatements
08/14/2003WO2003066001A2 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
08/14/2003WO2003066000A2 Formulation comprising bioactive agents and method of using same
08/14/2003WO2003065982A2 Engineering absorption of therapeutic compounds via colonic transporters
08/14/2003WO2003065980A2 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
08/14/2003WO2003065928A2 Therapeutic polyesters and polyamides
08/14/2003WO2003065806A1 New immunoeffector compounds
08/14/2003WO2003045437A8 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
08/14/2003WO2003045331A3 Formulations for oral administration of cromolyn sodium
08/14/2003WO2003043647A3 A plant extract active as an immunostimulating agent
08/14/2003WO2003043586A3 Compositions for sustained action product delivery
08/14/2003WO2003035237A3 Compounds for use as surfactants
08/14/2003WO2003035177A3 Optimal polymer mixtures for gastric retentive tablets
08/14/2003WO2003032973A3 Composition comprising paracetamol and a bitterness masking component
08/14/2003WO2003030935A3 Adjuvants for nucleic acid vaccines
08/14/2003WO2003028648B1 Veterinaire florfenicol formulation that is syringeable under cold weather conditions
08/14/2003WO2003022995A3 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
08/14/2003WO2003015699A3 Topical compositions and methods for treating pain
08/14/2003WO2003002069A3 Intradermal delivery of vaccines and gene therapeutic agents via microcannula
08/14/2003WO2003000202A3 Particles for inhalation having rapid release properties
08/14/2003WO2002096374A3 Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
08/14/2003WO2002083176A3 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
08/14/2003WO2002074336A3 Influenza vaccine formulations for intradermal delivery
08/14/2003WO2002058733B1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
08/14/2003WO2002048377A3 Polynucleotide encoding chimeric protein and related vectors, cells, and methods of expression thereof
08/14/2003WO2002026779A3 A fibrin/fibrinogen-binding conjugate
08/14/2003US20030153731 Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
08/14/2003US20030153724 Lactic acid polymer and process for producing the same
08/14/2003US20030153622 Ophthalmic solution and contact lens solution
08/14/2003US20030153621 Administering mixtures of 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) and carriers comprising glycerides or fatty esters as controllers of endothelial growth factors
08/14/2003US20030153614 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
08/14/2003US20030153613 Hypotensive agents for eye, using an aclurea indole compounds, potassium channel blockers; glaucoma
08/14/2003US20030153603 Agent for enhancing accumulation of drugs in tumor tissues
08/14/2003US20030153585 Comprises low water soluble 4-(4-(3-chloro-4-methoxybenzyl-amino)-benzo(4,5)thieno(2,3-d)pyrimidin-2 -yllcyclohexane-carboxylic acid; improved oral administration, bioavailability
08/14/2003US20030153581 Stabilized difloxacin injectable solution
08/14/2003US20030153547 Polymeric micellar structure
1 ... 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 ... 1712